Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies

Fig. 2

Progression-free survival (PFS) (a) and overall survival (OS) (b) in melanoma patients undergoing anti-PD-1 antibodies based on severity of irAE The patients who experienced no irAEs, mild irAEs (grade 1–2), and severe irAEs (grade 3–5) had significantly different PFS (p = 0.001) and OS (p < 0.001). The patients with mild irAEs showed favorable survival and those with severe irAEs showed unfavorable survival. The numbers below the charts correspond to patients at risk at each time point. irAEs, immune-related adverse events

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us